Exercise, metformin and hypoglycaemia: A neglected entity

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 2, 2005, Pages 106-108

  Omari, Abdullah ^a   Yue, Dennis K ^a,b   Twigg, Stephen M ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARBOHYDRATE; FOLIC ACID; GLUCOSE; HEMOGLOBIN A1C; INDAPAMIDE; INSULIN; METFORMIN; METOPROLOL; OMEPRAZOLE; RAMIPRIL; SULFONYLUREA;

ADULT; ANGINA PECTORIS; ARTICLE; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE REDUCTION; EXERCISE; FEMALE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LIFESTYLE; MEDICAL ASSESSMENT; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; RISK FACTOR; TREATMENT OUTCOME;

EID: 19144369899     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050021001     Document Type: Article

References (17)

1. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-9.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.
3. Fruehwald-Schultes B, Kern W, Oltmanns KM et al. Metformin does not adversely affect hormonal and symptomatic responses to recurrent hypoglycemia. J Clin Endocrinol Metab 2001; 86:4187-92.
4. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
5. Campbell RK, White JR Jr, Saulie BA. Metformin: a new oral biguanide. Clin Ther 1996;18:360-71.
6. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999; 58(suppl 1):31-9.
7. UK Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
8. Zitzmann S, Reimann IR, Schmechel H. Severe hypoglycemia in an elderly patient treated with metformin. Int J Clin Pharmacol Ther 2002;40: 108-10.
9. UK Prospective Diabetes Study (UKPDS) Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
10. UK Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-75.
11. Radziuk J, Bailey CJ, Wiernsperger NF, Yudkin JS. Metformin and its liver targets in the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:151-69.
12. Zou MH, Kirkpatrick SS, Davis BJ et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo: Role of mitochondrial reactive nitrogen species. J Biol Chem 2004;279:43940-51.
13. Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J. Captopril and insulin sensitivity. Ann Intern Med 1985;102:134-5.
14. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.[see comment]. Lancet 1995;345:1195-8.
15. White JR Jr, Hartman J, Campbell RK. Drug interactions in diabetic patients. The risk of losing glycemic control. Postgrad Med 1993;93:131-2.
16. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103:491-7.
17. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15:42-6.